MedPath

CytoMed Therapeutics

🇸🇬Singapore
Ownership
-
Employees
34
Market Cap
$18.3M
Website
Introduction

CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

Phase 1
Recruiting
Conditions
Malignancy
Relapsed Cancer
Cancer
Refractory Cancer
Interventions
Biological: Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
First Posted Date
2022-03-31
Last Posted Date
2024-11-22
Lead Sponsor
CytoMed Therapeutics Pte Ltd
Target Recruit Count
12
Registration Number
NCT05302037
Locations
🇸🇬

National University Hospital, Singapore, Singapore

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Phase 1
Conditions
Prostate Cancer
Colorectal Cancer
Triple Negative Breast Cancer
Gastric Cancer
Sarcoma
Nasopharyngeal Carcinoma
First Posted Date
2019-09-27
Last Posted Date
2019-09-27
Lead Sponsor
CytoMed Therapeutics Pte Ltd
Target Recruit Count
10
Registration Number
NCT04107142
Locations
🇲🇾

Landmark Medical Centre, Johor Bahru, Johor, Malaysia

News

CytoMed Therapeutics Advances Novel CAR Gamma Delta T Cell Therapy to Phase I Dose Level 2

CytoMed Therapeutics successfully completed dose level 1 of its first-in-human Phase I ANGELICA trial for CTM-N2D therapy in four late-stage cancer patients.

TC Biopharm Leads Gamma Delta T Cell Therapy Development with Over 25 Clinical Programs Worldwide

TC Biopharm's OmnImmune is advancing through a pivotal Phase 2/3 trial for acute myeloid leukemia, representing one of the most advanced gamma delta T cell therapies globally.

CytoMed and SunAct Partner to Advance Gamma Delta T-Cell Therapy for Solid Tumors in India

CytoMed Therapeutics and SunAct Cancer Institute collaborate to evaluate allogeneic gamma delta T cells for solid tumor treatment in a Phase 2 trial.

CytoMed's ANGELICA Trial: Revolutionizing Cancer Treatment with Off-the-Shelf Gamma-Delta T Cell Therapy

CytoMed Therapeutics launches the ANGELICA trial, utilizing donor-derived gamma-delta T cells to target solid tumors resistant to standard treatments.

CytoMed Therapeutics Initiates Phase I Trial of CTM-ONC in Solid Tumors

CytoMed Therapeutics has begun its Phase I ANGELICA trial, evaluating CTM-ONC in patients with advanced solid tumors.

CytoMed Therapeutics' ANGELICA Trial Receives Approval for Phase I Study in Advanced Cancers

CytoMed Therapeutics has received full approval for its Phase I ANGELICA trial, evaluating allogeneic CAR-T cell therapy in advanced cancers.

Canadian-Developed CAR T-Cell Therapy Targeting CD22 Heads to Clinical Trials

The National Research Council of Canada has developed a novel CAR T-cell therapy targeting the CD22 protein on B-cell leukemia and lymphoma cells, offering hope for patients who failed previous CD19-targeted treatments.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.